BACKGROUND: In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom. Vaccination was offered to 45 individuals with an initial assessment of high exposure risk. METHODS: Approval for rapid expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine as an unlicensed emergency medicine was obtained from the relevant authorities. An observational follow-up study was carried out for 1 year following vaccination. RESULTS: Twenty-six of 45 individuals elected to receive vaccination between 10 and 11 October 2015 following written informed consent. By day 14, 39% had seroconverted, increasing to 87% by day 28 and 100% by 3 months, although these responses were not always sustained. Neutralizing antibody responses were detectable in 36% by day 14 and 73% at 12 months. Common side effects included fatigue, myalgia, headache, arthralgia, and fever. These were positively associated with glycoprotein-specific T-cell but not immunoglobulin (Ig) M or IgG antibody responses. No severe vaccine-related adverse events were reported. No one exposed to the virus became infected. CONCLUSIONS: This paper reports the use of the rVSV-ZEBOV vaccine given as an emergency intervention to individuals exposed to a patient presenting with a late reactivation of EVD. The vaccine was relatively well tolerated, but a high percentage developed a fever ≥37.5°C, necessitating urgent screening for Ebola virus, and a small number developed persistent arthralgia.
BACKGROUND: In October 2015, 65 people came into direct contact with a healthcare worker presenting with a late reactivation of Ebola virus disease (EVD) in the United Kingdom. Vaccination was offered to 45 individuals with an initial assessment of high exposure risk. METHODS: Approval for rapid expanded access to the recombinant vesicular stomatitis virus-Zaire Ebola virus (rVSV-ZEBOV) vaccine as an unlicensed emergency medicine was obtained from the relevant authorities. An observational follow-up study was carried out for 1 year following vaccination. RESULTS: Twenty-six of 45 individuals elected to receive vaccination between 10 and 11 October 2015 following written informed consent. By day 14, 39% had seroconverted, increasing to 87% by day 28 and 100% by 3 months, although these responses were not always sustained. Neutralizing antibody responses were detectable in 36% by day 14 and 73% at 12 months. Common side effects included fatigue, myalgia, headache, arthralgia, and fever. These were positively associated with glycoprotein-specific T-cell but not immunoglobulin (Ig) M or IgG antibody responses. No severe vaccine-related adverse events were reported. No one exposed to the virus became infected. CONCLUSIONS: This paper reports the use of the rVSV-ZEBOV vaccine given as an emergency intervention to individuals exposed to a patient presenting with a late reactivation of EVD. The vaccine was relatively well tolerated, but a high percentage developed a fever ≥37.5°C, necessitating urgent screening for Ebola virus, and a small number developed persistent arthralgia.
Authors: Fatorma K Bolay; Greg Grandits; H Clifford Lane; Stephen B Kennedy; Melvin P Johnson; Mosoka P Fallah; Barthalomew Wilson; Wissedi S Njoh; Laura A McNay; Lisa E Hensley; Elizabeth S Higgs Journal: J Infect Dis Date: 2019-04-19 Impact factor: 5.226
Authors: Lieselotte Cnops; Michèle Gerard; Olivier Vandenberg; Sigi Van den Wijngaert; Leo Heyndrickx; Elisabeth Willems; Kathy Demeulemeester; Hilde De Clerck; Anne Dediste; Steven Callens; Paul De Munter; Erika Vlieghe; Emmanuel Bottieau; Francoise Wuillaume; Marjan Van Esbroeck; Kevin K Ariën Journal: Clin Infect Dis Date: 2015-02-18 Impact factor: 9.079
Authors: Michael Jacobs; Emma Aarons; Sanjay Bhagani; Ruaridh Buchanan; Ian Cropley; Susan Hopkins; Rebecca Lester; Daniel Martin; Neal Marshall; Stephen Mepham; Simon Warren; Alison Rodger Journal: Lancet Infect Dis Date: 2015-08-25 Impact factor: 25.071
Authors: Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen Journal: Lancet Date: 2015-08-03 Impact factor: 79.321
Authors: Karen K Wong; Richard T Davey; Angela L Hewlett; Colleen S Kraft; Aneesh K Mehta; Mark J Mulligan; Allison Beck; William Dorman; Christopher J Kratochvil; Lilin Lai; Tara N Palmore; Susan Rogers; Philip W Smith; Anthony F Suffredini; Mark Wolcott; Ute Ströher; Timothy M Uyeki Journal: Clin Infect Dis Date: 2016-04-26 Impact factor: 9.079
Authors: Simon A Weller; Daniel Bailey; Steven Matthews; Sarah Lumley; Angela Sweed; Derren Ready; Gary Eltringham; Jade Richards; Richard Vipond; Roman Lukaszewski; Phillippa M Payne; Emma Aarons; Andrew J Simpson; Emma J Hutley; Tim Brooks Journal: J Clin Microbiol Date: 2015-11-04 Impact factor: 5.948
Authors: Katie Ewer; Tommy Rampling; Navin Venkatraman; Georgina Bowyer; Danny Wright; Teresa Lambe; Egeruan B Imoukhuede; Ruth Payne; Sarah Katharina Fehling; Thomas Strecker; Nadine Biedenkopf; Verena Krähling; Claire M Tully; Nick J Edwards; Emma M Bentley; Dhanraj Samuel; Geneviève Labbé; Jing Jin; Malick Gibani; Alice Minhinnick; Morven Wilkie; Ian Poulton; Natalie Lella; Rachel Roberts; Felicity Hartnell; Carly Bliss; Kailan Sierra-Davidson; Jonathan Powlson; Eleanor Berrie; Richard Tedder; Francois Roman; Iris De Ryck; Alfredo Nicosia; Nancy J Sullivan; Daphne A Stanley; Olivier T Mbaya; Julie E Ledgerwood; Richard M Schwartz; Loredana Siani; Stefano Colloca; Antonella Folgori; Stefania Di Marco; Riccardo Cortese; Edward Wright; Stephan Becker; Barney S Graham; Richard A Koup; Myron M Levine; Ariane Volkmann; Paul Chaplin; Andrew J Pollard; Simon J Draper; W Ripley Ballou; Alison Lawrie; Sarah C Gilbert; Adrian V S Hill Journal: N Engl J Med Date: 2015-01-28 Impact factor: 91.245
Authors: Anne Rechtien; Laura Richert; Hadrien Lorenzo; Gloria Martrus; Boris Hejblum; Christine Dahlke; Rahel Kasonta; Madeleine Zinser; Hans Stubbe; Urte Matschl; Ansgar Lohse; Verena Krähling; Markus Eickmann; Stephan Becker; Rodolphe Thiébaut; Marcus Altfeld; Marylyn M Addo Journal: Cell Rep Date: 2017-08-29 Impact factor: 9.423
Authors: Christine Dahlke; Rahel Kasonta; Sebastian Lunemann; Verena Krähling; Madeleine E Zinser; Nadine Biedenkopf; Sarah K Fehling; My L Ly; Anne Rechtien; Hans C Stubbe; Flaminia Olearo; Saskia Borregaard; Alen Jambrecina; Felix Stahl; Thomas Strecker; Markus Eickmann; Marc Lütgehetmann; Michael Spohn; Stefan Schmiedel; Ansgar W Lohse; Stephan Becker; Marylyn M Addo Journal: EBioMedicine Date: 2017-04-05 Impact factor: 8.143